Oversight Chairman Greenwood Familiar With Third-Party Review Program
This article was originally published in The Gray Sheet
Executive Summary
Any legislative proposal to expand FDA's third-party review program to applications containing clinical data would have a powerful ally in Rep. Jim Greenwood (R-Penn.), the newly named chair of the House Energy and Commerce/Oversight Subcommittee.